Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Alzheimer’s to Benefit from Landmark MRC-AstraZeneca Compound Collaboration

Published: Tuesday, November 06, 2012
Last Updated: Tuesday, November 06, 2012
Bookmark and Share
A study to investigate Alzheimer’s disease led by scientists at the University of Bristol has been awarded funding by the Medical Research Council (MRC).

The MRC has announced funding of £7 million for 15 research projects awarded through its ground-breaking collaboration with innovative pharmaceutical company AstraZeneca, which gave academic researchers unprecedented access to 22 chemical compounds.

The researchers led by Seth Love, Professor of Neuropathology in the School of Clinical Sciences, will investigate whether a compound originally evaluated by AstraZeneca for the treatment of prostate cancer could delay, or even reverse, the progression of Alzheimer’s disease by improving blood flow through the brain.

Alzheimer’s is the most common form of dementia. It is thought to affect around half a million people in the UK and its occurrence in the population is on the rise. It occurs when protein plaques and tangles develop in the brain, damaging the nerve cells. No-one knows exactly what causes the disease, in which there is build-up of a protein called amyloid beta (Abeta) in the brain.

Professor Love and his colleagues have been investigating why blood flow through the brain is reduced in people with Alzheimer’s. The more severe this reduction, the worse their symptoms and the more rapidly the disease progresses. In recent studies the group has found that the Abeta causes cells in the brain to overproduce enzymes that act on blood vessels in the brain and cause them to narrow.

By blocking the action of these enzymes, the scientists hope they can restore blood flow to the brain and improve cognitive function (or at least slow the decline). This is a completely new approach to treating Alzheimer’s as most people are currently treated with drugs that increase levels of chemical messengers known as neurotransmitters in the brain.

This Bristol-based collaborative study will test the AstraZeneca compound (zibotentan), and another drug (losartan) developed to treat high blood pressure, to assess whether they are capable of blocking the effects of Abeta on brain blood flow. If successful, the researchers hope to secure funds to carry out a randomised controlled trial in patients with Alzheimer’s disease to see whether zibotentan can halt or slow the dementia and improve their quality of life.

Professor Love said: “We were delighted to have the chance to collaborate with AstraZeneca on such an exciting project. We now have a great opportunity to test a fundamentally new approach to Alzheimer’s treatment that if successful could be rapidly translated into the clinic.”

The MRC-AstraZeneca compound collaboration was first announced by Prime Minister David Cameron in December 2011 as part of the UK Life Sciences Strategy.

AstraZeneca made 22 of its chemical compounds available free-of-charge to scientists, who were encouraged to apply for MRC funding to use them in medical research with the ultimate aim of benefitting patients. AstraZeneca had conducted early trials of these compounds and validated their use for future research, but had put them on hold for further development.  This collaboration extends the possible application of these compounds for use in new areas.

Professor Patrick Johnston, Chair of the MRC’s Translational Research Group, said: “The quality of applications we received for the MRC-AstraZeneca collaboration was higher than we could ever have hoped and we are delighted to be funding 15 excellent projects. Thanks to the generosity of AstraZeneca, UK scientists will be able to carry out medical research that otherwise may never have been possible. Not only will this bring benefits for patients in the form of more effective medicines and a better understanding of disease, but it has also allowed academic researchers to forge new partnerships with industry, which will give rise to future collaboration across the life sciences sector.”

Martin Mackay, President of AstraZeneca Research and Development, said: “AstraZeneca strives to realise the full potential of its portfolio by collaborating with research experts worldwide in our search for new and effective medicines that can benefit patients. Partnering across government, academia and industry is a critical way to spur additional scientific innovation and the delivery of new treatments for people who desperately need them.”

David Willetts, Minister for Universities and Science, said: “This landmark collaboration will see our leading scientists working with industry to find new insights into disease. It will speed up the search for innovative treatments and keep the UK at the forefront of biomedical research, which will in turn drive growth and deliver benefits for patients.”

Sharmila Nebhrajani, Chief Executive of the Association of Medical Research Charities said: “From serious but common conditions such as Alzheimer’s to rarer diseases including motor neurone disease and muscular dystrophy, we still have only a limited understanding of the way diseases develop and few therapies available for patients. Scientific advance is rooted in collaboration. The £7 million funding announced today allows scientists access to previously unavailable compounds that may hold the key to understanding some highly debilitating diseases. Patients are anxiously waiting for new therapies, and collaborations that speed up the time it takes for medicines to be developed and become available to the public are especially welcome. Medical research charities, which themselves invest over £1 billion in scientific research each year and have dedicated patient supporters, are also keen to pool our resources with industry and public funders to maximise the impact of this investment.”

After looking at over 100 expressions of interest, the MRC received 23 full funding proposals. The applications were assessed by the MRC, independently of AstraZeneca through international expert peer review, and the 15 successful proposals were selected on the basis of scientific quality and importance.

The rights to intellectual property (IP) generated using the compounds will vary from project to project, but will be equitable and similar to those currently used in academically-led research. AstraZeneca will retain its existing rights relating to the compounds and any new research findings by the academic institution will be owned by the academic institution.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Monday, May 23, 2016
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Thursday, May 05, 2016
Autism Genes Are In All Of Us
Study suggests that genetic risk contributing to autism exists in all of us.
Tuesday, March 22, 2016
Genome Studies Identify Lifestyle Risks for Diseases
Genome wide association studies (GWAS) scan the entire genome in order to pinpoint genetic variants associated with a particular disease.
Wednesday, February 17, 2016
Ocean Acidification Makes Coralline Algae Less Robust
Ocean acidification (the ongoing decrease in the pH of the Earth’s oceans, caused by the uptake of CO2 from the atmosphere), is affecting the formation of the skeleton of coralline algae which play an important part in marine biodiversity, new research from the University of Bristol has found.
Wednesday, February 10, 2016
Gene Variation Identified for Teen Binge-Eating
Researchers have identified a gene variant which can lead to teenage binge eating, they hope that their work will inform the development of future preventative measures.
Wednesday, July 22, 2015
What Causes Immune Cell Migration To Wounds
Study shows triggers which lead immune cells to react and respond to wounded sites.
Friday, May 29, 2015
Fighting Prostate Cancer with a Tomato-Rich Diet
New research suggests that men who eat over 10 portions of tomatoes a week have an 18% lower risk of developing prostate cancer.
Thursday, August 28, 2014
Breakthrough Shows How DNA is ‘Edited’ to Correct Genetic Diseases
An international team of scientists has made a major step forward in our understanding of how enzymes 'edit' genes, paving the way for correcting genetic diseases in patients.
Wednesday, May 28, 2014
Deciphering the Role of Fat Stem Cells in Obesity and Diabetes
New study will examine stem cells to pinpoint how excess fat is stored, potentially paving the way for new treatments to combat obesity-linked diseases.
Wednesday, May 21, 2014
Molecular Biology Mystery Unravelled
Machinery responsible for the entry of proteins into cell membranes.
Saturday, February 22, 2014
Beauty and the Lab: Scientists Reveal the Art of Science
From a heart-shaped cell nucleus to a 3D molecular syringe, creative scientists have revealed the beauty found in complex and technical research.
Monday, December 16, 2013
New Swine Influenza Project to Better Understand Virus Transmission
The Pirbright Institute in Surrey has been awarded £4.4 million to work with researchers from universities on a long-term study on the transmission of swine influenza.
Friday, December 13, 2013
Global Carbon Dioxide Emissions to Reach 36 Billion Tonnes in 2013
Global emissions of carbon dioxide from the combustion of fossil fuels will reach 36 billion tonnes for the year 2013 – a level unprecedented in human history.
Tuesday, November 26, 2013
Human Neural Stem Cells Could Meet the Clinical Problem of Critical Limb Ischemia
New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels.
Monday, November 25, 2013
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos